By 2030, it is anticipated that the Australia dermatology drugs market will reach a value of $516 Mn from $204 Mn in 2022, growing at a CAGR of 12.3% during 2022-2030. The market is primarily dominated by local players such as Faulding, Bioscience International, Aspen Pharmacare, and Alpha pharm. The market is driven by an aging population, disparities in universal health coverage, and the launch of new and innovative drugs. This market is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.
The legalization of medical cannabis in Canada has resulted in the growth of Canada cannabis for GI diseases market. Cannabis can be used to treat irritable bowel disease, inflammatory bowel diseases, and colitis. The market is segmented by application and by product type.
The rising awareness about menopausal symptoms and their consequences on the health of Indian women is driving the growth of the India menopause treatment market during the forecast period. Hormone therapy, Gabapentin, and Clonidine are major treatment options for menopause in India.
France's biosimilars market size was valued at $0.5 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 21.4% from 2022 to 2030 and will reach $2.4 Bn in 2030. The market is segmented by product type and indication type. The France Biosimilars market will grow with the increased incidence of chronic illnesses, rising healthcare expenses, and the demand for affordable biologic medicine substitutes. The key market players are Sanofi, Pfizer, Biogen, Mylan, Amgen, and others.
This report presents a strategic analysis of the Australia Antibacterial (Antibiotics) Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Australian antibacterial (Antibiotics) Drugs Market, offering unmatched value, accuracy, and expert insights.
The current demographics in UK make it an ideal market as the demand for anti-aging and overall skincare products is high thereby resulting in the growth of the UK anti-aging market during the forecast period. The market is segmented by product type, service type, route of administration and device type.
The US breast cancer market is expected to witness growth from $473 Mn in 2022 to $1,083 Mn in 2030 with a CAGR of 10.9% for the year 2022-2030. Increased prevalence of breast cancer and technologically advanced therapeutics are the major growth drivers for the expansion of the market in US.
The India osteoporosis drugs market is projected to grow during the forecast period because of the high incidence of osteoporosis in India and due to the rising geriatric population. The market is segmented by drug class and by route of administration. Some of the key players in the market are Cadila pharmaceuticals and Dr. Reddy's Laboratories.
The growing prevalence of Alzheimer's disease in elderly women in Australia is responsible for the growth of Australia Alzheimer's disease market. The market is segmented by product, drug, and distribution channel. Roche, Eisai, and Novartis are some of the key competitors in the market.
The Abu Dhabi oncology drugs market is projected to grow from $296.3 Mn in 2022 to $635.2 Mn in 2030 with a CAGR of 10% for the year 2022-2030. Geriatric population growth and technological advancements in the treatment of cancer in Abu Dhabi are the major market drivers. AstraZeneca and Pfizer are the key players in the Abu Dhabi oncology drugs market.
The Canada dermatology prescription market is projected to grow from $459.7 Mn in 2022 to $927.4 Mn in 2030 with a CAGR of 9.2% for the year 2022-2030. Technological advancements and a strong pipeline of drugs are the possible market drivers for the growth of the market during the forecast period.